According to the British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2020, three commonly used biological agents were selected: the IL-17A inhibitor SEC, IL-12/23 inhibitor UST and TNFα inhibitor ADA. This evidence concerns the gene IL17A and psoriasis.